

## CANADIAN CANCER TRIALS GROUP

## MELANOMA

DISEASE SITE COMMITTEE MEETING AGENDA

THE CHELSEA HOTEL, TORONTO, ONTARIO

ROOM: SCOTT

DATE: SUNDAY MAY 1ST, 2016

TIME: 8:00 AM – 12:00 PM

CHAIRS: DR. TERESA PETRELLA, DR. ALAN SPATZ

(12:00 PM – 1:00 PM EXECUTIVE COMMITTEE MEETING – CLOSED)

8:00 - 8:10 am	<b>Welcome and Approval of 2015 Spring Meeting Minutes</b>	T. Petrella
8:10 - 9:10 am	<b>Trial Updates</b> <ul style="list-style-type: none"> <li>• MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG) <span style="float: right;">T. Petrella</span></li> <li>• MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance) <span style="float: right;">M.Butler</span></li> <li>• MEC.5 – A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (SWOG) <span style="float: right;">T. Petrella</span></li> <li>• IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases <span style="float: right;">T. Petrella</span></li> <li>• IND225 – A Phase II Study of the Assessment of Response To Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker <span style="float: right;">T. Petrella</span></li> <li>• ME13 – A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP) <span style="float: right;">Tara Baetz/ Xinni Song</span></li> </ul>	
9:10 - 10:15 am	<b>New Proposals</b> <ul style="list-style-type: none"> <li>• Update on the Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma <span style="float: right;">F. Wright</span></li> <li>• Management of Immunotherapy Side Effects <span style="float: right;">J. Walker</span></li> </ul>	

- 9:10 - 10:15 am     **New Proposals Continued**
- Intralesional IL-2 plus or minus nivolumab for the treatment of intrinsic cutaneous malignant melanoma     C. Giacomantonio
  - Neoadjuvant Proposal: combination of PD-1 and IDO inhibitors     X. Song
  - A randomized phase II trial of Temozolomide and Cisplatin versus Nivolumab (BMS-936558) in patients with completely resected mucosal melanoma     D. Vicus
  - Neoadjuvant combined immunotherapy and targeted therapy in resectable, locally advanced Stage IIIb-c and oligometastatic melanoma     C. Nessim
- 10:15 - 10:30 am     **Break**
- 10:30 - 11:15 am     **Special Topics**  
*(Closed - Canadian Cancer Trials Group Members Only)*
- EXACTIS / CCTG Melanoma Collaboration     R. Fajzel / D. O'Donnell
- 11:15 - 12:00 pm     **Melanoma Site Strategic Planning**  
*(Closed - Canadian Cancer Trials Group Members Only)*
- Background     J. Dancey
  - Discussion     T. Petrella
- 12:00 pm     **Meeting Adjourned**
- 12:00 - 1:00 pm     *Executive Committee meeting to follow (closed)*